BBR is being examined in at least 35 clinical trials for treatment of: cardiovascular diseases, colorectal adenoma reoccurrence, diabetes, defective endothelial function, glucose metabolism/metabolic syndrome, Helicobacter pylori infection, hyperglycemia/glycemic control, hyper-lipemia, insulin sensitivity and insulin secretion, inflammation, non-alcoholic fatty liver disease, platelet aggregation, polycystic ovary syndrome and schizo-phrenia. The gene discussed is INS; the disease is polycystic ovary syndrome.